Investment structuring in biotech startups

Introduction

Investment structuring in biotechnology startups refers to the legal, financial and corporate arrangements through which new biotechnology companies obtain capital to develop scientific innovations, conduct research, manufacture biological products and commercialise technologies. Biotechnology startups generally require substantial investment because research and development, clinical trials, laboratory infrastructure, regulatory approvals and intellectual property protection involve significant expenditure.

Unlike many conventional businesses, biotechnology startups may take several years to generate revenue. Investors therefore need suitable financial structures that balance investment risks, ownership rights, control over business decisions and potential returns.

Investment structuring establishes the relationship between founders, venture capitalists, angel investors, institutional investors and strategic business partners. A properly structured investment arrangement can support innovation while protecting the legal and financial interests of all stakeholders.

Meaning and importance of investment structuring

Investment structuring involves determining how capital will enter a startup, what ownership or financial rights investors will receive and how the company will use the funds.

In biotechnology, investment may be required for:

Research and development of new biological technologies.

Development of pharmaceutical products and medical devices.

Clinical trials and regulatory approvals.

Laboratory equipment and specialised infrastructure.

Patent registration and intellectual property protection.

Commercial production and international expansion.

Investment agreements must consider the long development period and uncertainty associated with scientific discoveries.

Major investment structures in biotechnology startups

1. Equity financing

Equity financing involves raising capital by issuing shares in the company. Investors receive ownership interests in exchange for their investment.

For example, a biotechnology startup developing a new diagnostic technology may issue shares to venture capital investors. The investors become shareholders and may receive voting rights, dividend entitlements and participation in future profits.

Equity financing is useful because it does not generally require repayment like an ordinary loan. However, founders may experience dilution of their ownership.

2. Convertible instruments

Convertible instruments provide funding that may convert into equity under specified conditions.

Common examples include convertible notes and other convertible securities. These arrangements allow startups to obtain capital before determining a final company valuation.

Their terms may include conversion discounts, valuation caps, maturity dates and interest provisions.

3. Venture capital financing

Venture capital firms invest in startups with significant growth potential. Biotechnology companies may attract venture capital because successful scientific innovations can create valuable intellectual property and commercial opportunities.

Venture capital agreements commonly include:

Board representation.

Information and inspection rights.

Reserved matters requiring investor consent.

Anti-dilution provisions.

Liquidation preferences.

Restrictions on certain share transfers.

These provisions provide investors with protection while allowing founders to continue managing research and business operations.

4. Strategic partnerships

Biotechnology startups may receive investment from pharmaceutical companies, medical technology businesses and research institutions.

Such partnerships may include licensing arrangements, joint ventures, research collaboration and milestone-based payments.

These structures provide access to capital, technology, manufacturing facilities and distribution networks.

5. Government grants and research funding

Government agencies and scientific institutions may provide grants or financial assistance for biotechnology research.

Unlike equity investment, grants generally do not require the transfer of company ownership. However, recipients must comply with funding conditions, reporting obligations and restrictions on the use of funds.

Legal framework governing biotech startup investments

1. Companies Act, 2013

The Companies Act, 2013 provides the principal corporate framework for investment structuring in India.

Important provisions include:

Section 42: Private placement of securities.

Section 62: Further issue of share capital.

Section 71: Regulation of debentures.

Section 179: Powers of the board of directors.

Section 188: Regulation of related-party transactions.

These provisions help establish lawful procedures for raising capital and managing shareholder relationships.

2. SEBI regulations

The Securities and Exchange Board of India regulates securities markets and certain investment activities. The SEBI (Alternative Investment Funds) Regulations, 2012 provide the framework for venture capital funds and other alternative investment funds.

Biotechnology startups receiving investment from registered alternative investment funds must consider the applicable regulatory requirements.

3. Foreign investment regulations

Foreign investment in Indian biotechnology companies is governed by the Foreign Exchange Management Act, 1999, applicable RBI regulations and the Foreign Direct Investment Policy.

The permitted investment route depends on the nature of the business, applicable sectoral conditions and current government policy.

4. Intellectual property legislation

The Patents Act, 1970 and Copyright Act, 1957 are important for protecting qualifying biotechnology inventions, software and research-related works.

Investors frequently examine patent ownership, licensing arrangements, employee invention agreements and freedom-to-operate issues before investing.

Important case laws

1. Vodafone International Holdings BV v. Union of India (2012)

The Supreme Court of India examined the taxation of an offshore transaction involving indirect transfer of an Indian company's shares.

The judgment is relevant to biotechnology investment structuring because cross-border shareholding arrangements, holding companies and international investment structures may raise complex taxation and jurisdictional questions.

2. V.B. Rangaraj v. V.B. Gopalakrishnan (1992)

The Supreme Court of India considered the enforceability of restrictions on share transfers that were not incorporated into the company's articles of association.

The Court emphasised the importance of complying with the statutory corporate framework governing share transfers.

This decision is relevant to biotechnology startups because shareholder agreements frequently contain transfer restrictions, founder-lock-in provisions and investor exit arrangements. Such provisions should be properly reflected in corporate documents where legally required.

3. Messer Holdings Ltd. v. Shyam Madanmohan Ruia (2016)

The Bombay High Court considered contractual restrictions concerning share transfers and the relationship between shareholders' agreements and company law.

The judgment is relevant to investment structuring because it discusses the enforceability of negotiated shareholder arrangements and restrictions on the transfer of shares.

4. LIC of India v. Escorts Ltd. (1986)

The Supreme Court of India examined foreign investment regulation and the powers of governmental authorities under the foreign exchange regulatory framework.

The judgment is relevant to biotechnology startups receiving foreign investment because it demonstrates the importance of compliance with national foreign exchange laws and regulatory requirements.

Due diligence before investment

Investors generally conduct legal, financial, technical and regulatory due diligence before investing in a biotechnology startup.

Important areas include:

Verification of intellectual property ownership.

Examination of patents and licensing agreements.

Review of research and clinical trial documentation.

Assessment of regulatory approvals.

Verification of financial statements and liabilities.

Examination of employment and founder agreements.

Identification of pending litigation and compliance risks.

Scientific due diligence is particularly important because the commercial value of a biotechnology startup may depend heavily on the reliability of its research and development pipeline.

Challenges in investment structuring

Biotechnology startups face several investment-related difficulties. Research may fail despite substantial expenditure, regulatory approvals may be delayed and intellectual property disputes may affect commercialisation.

Another challenge is valuation. A startup with no commercial revenue may possess valuable patents or promising research, making conventional valuation methods less reliable.

Founders must also balance investor control with scientific independence. Excessive investor restrictions may interfere with long-term research decisions, while insufficient contractual protection may discourage investment.

Conclusion

Investment structuring in biotechnology startups is essential for securing capital, protecting intellectual property and establishing sustainable corporate governance. Equity financing, venture capital, convertible instruments, strategic partnerships and government grants provide different funding opportunities. Indian legislation, particularly the Companies Act, 2013, SEBI regulations and foreign investment rules, establishes the legal foundation for these arrangements. Judicial decisions such as Vodafone International Holdings BV v. Union of India, V.B. Rangaraj v. V.B. Gopalakrishnan and LIC of India v. Escorts Ltd. provide important principles concerning investment structures, shareholder rights and foreign investment regulation. A transparent and legally compliant investment structure can strengthen investor confidence and support long-term biotechnology innovation.